FDA Clears AI-Powered Ultrasound Tool for Fetal Biometric Measurements
Clarius OB AI reportedly provides estimates of fetal age, weight and growth intervals based on automated fetal biometry measurements available through handheld ultrasound.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Clarius OB AI, an AI-powered handheld ultrasound tool that may bolster access for use of the technology in monitoring fetal wellbeing.
Trained on over 30,000 fetal ultrasound images, Clarius OB AI automates appropriate caliper placement for the calculation of fetal biometry measurements and enables one to add the measurements to patient electronic medical records through the Clarius app, according to Clarius, the developer of Clarius OB AI.
Trained on over 30,000 fetal ultrasound images, the recently FDA-cleared Clarius OB AI tool automates appropriate caliper placement for the calculation of fetal biometry measurements and enables one to add the measurements to patient electronic medical records through the Clarius app. (Image courtesy of Clarius.)
Carolyn L. Gegor, CNN, MS, FACNM, called the Clarius OB AI tool an “excellent teaching modality” that could help reduce the learning curve with OB ultrasound for those who lack experience with ultrasound scanning.
"When I used Clarius OB AI while teaching OB ultrasound to a group of midwives, I was impressed by the accuracy of cursor placement on multiple scans, from crown rump length to biparietal diameter and femur length," noted Gegor, an ARDMS-certified midwife sonographer. "I found that after using the OB AI model, the students were more able to properly measure structures without the assistance of the AI.”
Clarius noted the Clarius OB AI tool is included with Clarius membership and available in the United States and Canada with the Clarius C3 HD3 handheld ultrasound device.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
